TimothyJosephVoorheesMD, MSCR

PubMed

• Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse la...
  Rossana Di Staso, Beatrice Casadei, Frederick L Locke, Michael Jain, Timothy J Voorhees
  Blood Cancer Journal. 2024-11-07
• SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program.
  Timothy J Voorhees, Evandro Bezerra, Nathan Denlinger, Samantha Jaglowski, Marcos de Lima
  Clinical Lymphoma, Myeloma & Leukemia. 2024-10-01
• 1 citations
  Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma.
  Nathan Denlinger, No-Joon Song, Xiaoli Zhang, Hyeongseon Jeon, Chelsea Peterson
  Blood Advances. 2024-06-25

Abstracts/Posters

• Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
  Timothy J Voorhees, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents
  Timothy J Voorhees, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  Timothy J Voorhees, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• High Risk Cytogenetic and Immunohistochemistry Findings in Monomorphic Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplant _ a Single Center ... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019